Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
News

One in Six US Drugs Will Soon Be Made in Israel

JERUSALEM (JTA) – Israel-based Teva Pharmaceutical Industries has completed its $40 billion purchase of the generic medicine division of Allergan, its chief competitor.

As part of the deal completed on Tuesday, Allergan received $33.4 billion in cash and 100.3 million shares of Teva stock.

Allergan’s Anda Inc is the 4th-largest distributor of generic pharmaceuticals in the U.S. Anda distributes generic, brand, specialty and over-the-counter pharmaceutical products from more than 300 manufacturers to pharmacies, nursing homes, hospitals, clinics and physician offices across the United States.

Teva is the world’s largest manufacturer of generic drugs. Anda will continue to operate as a standalone division, Teva said in a statement issued Tuesday.

Teva CEO Erez Vigodman said Tuesday in an interview with the French news agency AFP that the acquisition is part of a wider plan to become one of the “most competitive, fully integrated companies in the industry.”

He told AFP that, in the wake of the deal, “one in six prescriptions in the U.S. (will be) Teva, one in six in the U.K., one in eight in Germany.” He denied that the acquisition would lead to higher generic drug prices.

The sale is subject to anti-trust clearance. Teva reportedly will have to sell off 79 of its pharmaceutical products in order to come into compliance.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.